-8.1 | | Prss57 | '5 week' vs '1 week' in 'Jak2+/V617F; CRISPR/Cas9 mediated knockout of Dnmt3a' | genotype, time | RNA-seq of Jak2VF LSK cells transduced with Dnmt3a-Cas9-GFP lentivirus vs. emp-Cas9-GFP controls one week and five weeks post methylcellulose plating |
-7.3 | | Prss57 | 'SMRT shRNA; CpG; 6 hour' vs 'none; none; 0 hour' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
5.6 | | Prss57 | 'α-GalCer; 2 microgram' vs 'none' in 'Cd1d homozyous knockout' | compound, genotype | CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells |
-5.5 | | Prss57 | 'CpG; 6 hour' vs 'none; 0 hour' in 'none' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
4.6 | | Prss57 | 'cancer' vs 'normal' in 'lymph node subcapsular sinus macrophage' | cell type, disease | RNA Sequencing of CD169+ lymph node macrophages isolated from naïve or tumor-bearing mice |
-4.4 | | Prss57 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
4.4 | | Prss57 | 'myeloid lineage restricted progenitor cell' vs 'long term hematopoietic stem cell' in 'Elp3fl/fl' | cell type, genotype | RNA-seq of long-term hematopoietic stem cells and myeloid progenitors of control mice or mice conditionally deficient for Trp53 or Elp3 or both genes in the hematopoietic system |
-4.4 | | Prss57 | 'SMRT shRNA' vs 'none' in 'none' at '0 hour' | RNA interference, stimulus, time | RNA-seq of Control and SMRT KD CD8α+ DCs at 0hr and 6hr CpG stimulation |
3.9 | | Prss57 | 'Id2_Id3_double knockout' vs 'wild type' in 'CD4+TCRb+CD8– cell; thymus' | cell type, genotype, organism part | Transcription profiling by high throughput sequencing of Id-proteins (Id2 and Id3) gene knockout cells |
-3.8 | | Prss57 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
3.6 | | Prss57 | 'Triple knockout (Zfp36-/-, TNFR1-/-, TNFR2-/-)' vs 'wild type' | genotype | Transcription profiling by high throughput sequencing of douple (TNFR1-/-/TNFR2-/-) and triple (Zfp36-/-/TNFR1-/-/TNFR2-/-) knockout mouse spleens |
3.4 | | Prss57 | 'MEF2C/D knockout' vs 'wild type genotype' in 'primary cell line; none' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-3.4 | | Prss57 | 'synovial sarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
3.3 | | Prss57 | 'MEF2C/D knockout' vs 'wild type genotype' in 'primary cell line; lipopolysaccharide; 10 nanogram per milliliter' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
3.1 | | Prss57 | '3110043O21Rik knockout; spleen' vs 'wild type genotype; spleen' | genotype, organism part, sampling site | RNAseq of coding RNA in the liver, spleen, kidney, abdominal muscle and gonadal adipose tissue of knock out mice and wild type controls. |
3 | | Prss57 | 'ABIN1[D485N] knock-in' vs 'wild type genotype' in 'classical monocyte' | cell type, genotype | RNA-seq of inflammatory monocytes, patrolling monocytes and neutrophils in wild type and ABIN1[D485N] mice |
2.9 | | Prss57 | 'co-cultured with hematopoietic stem cell for 9 days' vs 'non co-cultured for 9 days' in 'endothelial cell; expressing AKT1' | cell type, growth condition, phenotype | Transcription profiling by high throughput sequencing of murine bone marrow endothelial cells and bone marrow stroma, in vitro and in vivo, with and without hematopoietic stem cells co-culture |
2.8 | | Prss57 | 'hepatocyte-derived proliferative ducts (hepPDs)' vs 'hepatocyte' | cell type | Transcription profiling by high throughput sequencing of hepatocyte-derived progenitors cells in a mouse model of oval cell activation |
2.6 | | Prss57 | 'Cd1d homozyous knockout' vs 'wild type genotype' in 'α-GalCer; 2 microgram' | compound, genotype | CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells |
2.6 | | Prss57 | 'MEF2C/D knockout' vs 'wild type genotype' in 'primary cell line; lipopolysaccharide; 10 nanogram per milliliter and prostaglandin E2; 1 micromolar' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
-2.6 | | Prss57 | 'carotid body' vs 'adrenal medulla' | organism part | Expression profile of mouse carotid body and adrenal medulla [RNA-Seq] |
2.5 | | Prss57 | 'p150 subunit of CAF-1 siRNA knockdown' vs 'scrambled siRNA' | RNA interference | RNA-seq of control siRNA, p150 siRNA and p60 siRNA transfected mES cells |
2.5 | | Prss57 | 'uterine-specific Tsc2-null' vs 'wild type' in '17beta-estradiol' | genotype, treatment | Transcription profiling by high throughput sequencing of uterine-specific Tsc2-null mice |
-2.4 | | Prss57 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-2.3 | | Prss57 | 'erythroblast' vs 'hematopoietic stem cell' | cell type | Transcription profiling by array of primary megakaryocytes (MEG) and erythroblasts (ERY) developed from murine fetal liver hematopoietic stem cells |
-2.3 | | Prss57 | 'megakaryocyte' vs 'hematopoietic stem cell' | cell type | Transcription profiling by array of primary megakaryocytes (MEG) and erythroblasts (ERY) developed from murine fetal liver hematopoietic stem cells |
2.2 | | Prss57 | 'promyelocyte' vs 'hemopoietic stem cell' | cell type | Gene expression data from mouse hemopoietic stem cells (LSKs), promyelocytes, myelocytes and granulocytes. |
2.2 | | Prss57 | 'p60 subunit of CAF-1 siRNA knockdown' vs 'scrambled siRNA' | RNA interference | RNA-seq of control siRNA, p150 siRNA and p60 siRNA transfected mES cells |
-2.2 | | Prss57 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'F1.B6x129' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
2.1 | | Prss57 | 'MEF2C/D knockout' vs 'wild type genotype' in 'primary cell line; prostaglandin E2; 1 micromolar' | cell line, compound, genotype | Bulk RNA-seq of wild type and MEF2A or MEF2C/D knockout mouse bone marrow macrophages under different stimulation conditions |
2.1 | | Prss57 | 'doxorubicin; 17.5 milligram per kilogram body weight' vs 'vehicle' in 'scramble; podocyte' | cell type, compound, genotype | Transcription profiling to identify the role of MOF in primary MEFs and differentiated podocytes in response to Adriamycin |
-2 | | Prss57 | 'LDB1 knock-down with full-length Ldb1 construct' vs 'control shRNA' | RNA interference | Role of LDB1 in the transition from chromatin looping to transcription activation |
-1.9 | | Prss57 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'C57BL/6J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
-1.8 | | Prss57 | 'Col1a1-tetO-MLL/ENL' vs 'wild type' in 'precursor for granulocyte-macrophage progenitor cell' | cell type, genotype | Transcription profiling by high throughput sequencing of hematopoietic stem cells from a conditional-inducible mouse model of the MLL-ENL fusion oncogene |
-1.7 | | Prss57 | 'hematopoietic stem cell and hematopoietic multipotent progenitor cell' vs 'common myeloid progenitor' | cell type | Transcription profiling by high throughput sequencing between multipotent hematopoietic stem progenitor cells LS+K) and myeloid committed cells (LS−K) of the mouse bone marrow |
-1.6 | | Prss57 | 'LDB1 knock-down with Ldb1 delta 4/5 construct' vs 'control shRNA' | RNA interference | Role of LDB1 in the transition from chromatin looping to transcription activation |
-1.5 | | Prss57 | 'CD4-positive T cell' vs 'CD8-positive T cell' in 'Egr2-GFP knockin; Egr2-GFP high' | cell type, genotype, phenotype | RNAseq analysis of CD4 and CD8 T cells in response to vaccinia virus infection |
-1.4 | | Prss57 | 'pre-B acute lymphoblastic leukemia 8093; nilotinib; 3 day' vs 'pre-B acute lymphoblastic leukemia 8093; nilotinib; 0 day' | cell type, compound, time | Drug tolerance development of mouse Bcr/Abl pre-B ALL cells on irradiated MEFs |
1.2 | | Prss57 | '26 day' vs '0 day' | age | Gene expression profile of mouse differentiating embryonic stem cells (day 0, 6, 16, and 26) |
1.2 | | Prss57 | 'plasmacytoid dendritic cell; Ifnar1 knock out; specific pathogen free' vs 'plasmacytoid dendritic cell; wild type genotype; specific pathogen free' | cell type, genotype, growth condition | RNA sequencing of primary isolated unstimulated murine splenic DC1 and DC2 from specific pathogen free (SPF), Germ free (GF) and Interferon alpha/beta receptor 1 (Ifnar) knock out mice |
1.2 | | Prss57 | 'co-cultured with hematopoietic stem cell for 9 days' vs 'non co-cultured for 9 days' in 'stromal cell; expressing AKT1' | cell type, growth condition, phenotype | Transcription profiling by high throughput sequencing of murine bone marrow endothelial cells and bone marrow stroma, in vitro and in vivo, with and without hematopoietic stem cells co-culture |
-1.1 | | Prss57 | 'Cd1d homozyous knockout' vs 'wild type genotype' in 'none' | compound, genotype | CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells |
-1.1 | | Prss57 | 'Lmp7-/-Mecl1-/-' vs 'wild type' | genotype | Effect of LMP7 and MECL1-immunoproteasome subunits deficiency on the transcriptome of mouse bone marrow-derived dendritic cells |
-1.1 | | Prss57 | 'lung carcinoma' vs 'normal' in 'CD11b+Ly6G+ neutrophil' | cell type, disease | Transcriptome analysis of isolated stormal cells and tumor epithelial cells in mouse lung cancer by RNA-Seq |
1 | | Prss57 | 'Cbs knockout' vs 'wild type' | genotype | Gene expression profile of CD4-positive T cells from mouse Cbs knockout |
-1 | | Prss57 | 'Pabpn1 knockdown by shRNA' vs 'scrambled shRNA' | genotype | 3' RNA-seq of Pabpn1 knockdown in mouse Lin- Kit+ bone marrow cells |
1 | | Prss57 | 'acute myeloid leukemia' vs 'myeloproliferative disorder' | disease | Transcription profiling by high throughput sequencing of c-KIT+ splenocytes from murine acute myeloid leukemia and myeloproliferative neoplasm |
-1 | | Prss57 | '4-oxoretinoic acid; 5 micromolar' vs 'none' in 'Rarb -/-' | compound, genotype | RNA Seq of wildtype and Rarb KO HSCs after 24h of in vitro culture and treatment |